Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.
Open accessThe DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with idiopathic pulmonary fibrosis, treatment with nerandomilast stabilized lung function over a period of 12 weeks. METHODS: In this phase 3, double-blind trial, we randomly assigned patients with idiopathic pulmonary fibrosis in a 1:1:1 ratio to receive nerandomilast at a dose of 18 mg twice daily, nerandomilast at a dose of 9 mg twice daily, or placebo, with stratification according to background antifibrotic therapy (nintedanib or pirfenidone vs. none). The primary end point was the absolute change from baseline in forced vital capacity (FVC), measured in milliliters, at week 52. RESULTS: A total of 1177 patients underwent randomization, of whom 77.7% were taking nintedanib or pirfenidone at enrollment. Adjusted mean changes in FVC at week 52 were -114.7 ml (95% confidence interval [CI], -141.8 to -87.5) in the nerandomilast 18-mg group, -138.6 ml (95% CI, -165.6 to -111.6) in the nerandomilast 9-mg group, and -183.5 ml (95% CI, -210.9 to -156.1) in the placebo group. The adjusted difference between the nerandomilast 18-mg group and the placebo group was 68.8 ml (95% CI, 30.3 to 107.4; P<0.001), and the adjusted difference between the nerandomilast 9-mg group and the placebo group was 44.9 ml (95% CI, 6.4 to 83.3; P = 0.02). The most frequent adverse event in the nerandomilast groups was diarrhea, reported in 41.3% of the 18-mg group and 31.1% of the 9-mg group, as compared with 16.0% in the placebo group. Serious adverse events were balanced across trial groups. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, treatment with nerandomilast resulted in a smaller decline in the FVC than placebo over a period of 52 weeks. (Funded by Boehringer Ingelheim; FIBRONEER-IPF ClinicalTrials.gov number, NCT05321069.).
Overview
CoChat Summary
TL;DR
In this phase 3, double-blind trial, nerandomilast (BI 1015550), an oral preferential phosphodiesterase 4B inhibitor, reduced the 52-week decline in forced vital capacity compared with placebo in patients with idiopathic pulmonary fibrosis. Both the 18-mg and 9-mg twice-daily doses were superior to placebo, with diarrhea the most frequent adverse event.
Key findings
- Adjusted mean change in FVC at week 52 was −114.7 ml (95% CI, −141.8 to −87.5) with nerandomilast 18 mg, −138.6 ml (95% CI, −165.6 to −111.6) with nerandomilast 9 mg, and −183.5 ml (95% CI, −210.9 to −156.1) with placebo.
- Adjusted difference versus placebo was 68.8 ml (95% CI, 30.3 to 107.4; P<0.001) for the 18-mg dose and 44.9 ml (95% CI, 6.4 to 83.3; P=0.02) for the 9-mg dose.
- Diarrhea was the most frequent adverse event in the nerandomilast groups: 41.3% (18 mg) and 31.1% (9 mg) versus 16.0% with placebo; serious adverse events were balanced across trial groups.
- Of 1177 randomized patients, 77.7% were taking nintedanib or pirfenidone at enrollment.
Methods
- Phase 3, double-blind trial; patients with idiopathic pulmonary fibrosis were randomly assigned 1:1:1 to nerandomilast 18 mg twice daily, nerandomilast 9 mg twice daily, or placebo.
- Randomization was stratified according to background antifibrotic therapy (nintedanib or pirfenidone vs. none).
- Primary end point: absolute change from baseline in FVC (milliliters) at week 52; 1177 patients underwent randomization. (Funded by Boehringer Ingelheim; FIBRONEER-IPF, NCT05321069.)
Limitations
- Not stated in the paper (the provided text is the structured abstract and does not report a limitations section).
- Evident from the text: only the primary end point and the most frequent adverse event are reported here, with no detail on secondary outcomes, subgroup analyses, or the full safety profile; the abstract also does not report patient baseline characteristics or trial duration beyond the 52-week end point.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 12 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the adjusted difference between the nerandomilast 9-mg group and the placebo group was 44.9 ml (95% CI, 6.4 to 83.3; P = 0.02)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“-183.5 ml (95% CI, -210.9 to -156.1) in the placebo group”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted difference between the nerandomilast 18-mg group and the placebo group was 68.8 ml (95% CI, 30.3 to 107.4; P<0.001)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adjusted mean changes in FVC at week 52 were -114.7 ml (95% confidence interval [CI], -141.8 to -87.5) in the nerandomilast 18-mg group”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most frequent adverse event in the nerandomilast groups was diarrhea, reported in 41.3% of the 18-mg group and 31.1% of the 9-mg group, as compared with 16.0% in the placebo group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
3 more claims
Create a free account to see all 13 claims and every source verdict.
- Borderline: one of the tests for a substantial claim is unclear. 1
- Probably not a substantial claim. 3
- It may state two separate claims as one. 2
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The approved anti-fibrotic drugs nintedanib (Ofev®), pirfenidone (Esbriet®), and nerandomilast (Jascayd®) slow the rate of FVC decline2,4, but do not halt disease progression or restore lung function.”
From Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study (2026) · cites this paper as [4]
Experimental — accuracy not yet measured
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationGraham, B. L., Steenbruggen, I., Miller, M. R., Barjaktarevic, I. Z., Cooper, B. G., Hall, G. L., Hallstrand, T. S., Kaminsky, D. A., McCarthy, K., McCormack, M. C., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1590st · Cited by 4,305
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Self-citationStandardisation of the single-breath determination of carbon monoxide uptake in the lung
MacIntyre, N., Crapo, R. O., Viegi, G., Johnson, D. C., van der Grinten, C. P. M., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Enright, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034905 · Cited by 2,255
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Self-citationA graphical approach to sequentially rejective multiple test procedures
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3495 · Cited by 420
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
Richeldi, L., Azuma, A., Cottin, V., Hesslinger, C., Stowasser, S., Valenzuela, C., Wijsenbeek, M. S., Zoz, D. F., Voss, F., & Maher, T. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201737 · Cited by 236
Self-citationThe leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis
Selman, M., & Pardo, A. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109482 · Cited by 225
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
Maher, T. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A.-M., Kreuter, M., Oldham, J. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2503643 · Cited by 205
Self-citation
Cited by
Items 201–239 of 239
Omar, A., Evans, P., & Hutchinson, N.-X. (2026) · Thorax · doi:10.1136/thorax-2026-225299
Song, C., Jeong, Y., & Kim, T. (2026) · Animal Cells and Systems · doi:10.1080/19768354.2026.2677272
Ramot, Y., Steiner, M., Kronfeld, N., Fishman-Jacob, T., Timaner, M., & Nyska, A. (2026) · Toxicologic Pathology · doi:10.1177/01926233261462505
Inter‐Organ Communication in Pulmonary Fibrosis: Systemic Modifiers of a Lung‐Centered Disease
Wan, R., Qin, Z., Wang, Z., & Xu, K. (2026) · The FASEB Journal · doi:10.1096/fj.202603126
“Current antifibrotic therapies can only slow the decline in lung function in a subset of patients but are unable to cure the disease or reliably reverse established fibrosis [7].”
Murine models of pulmonary fibrosis: mechanisms, limitations and translational insights
Lou, K. F., Fulcer, M. M., Lotesto, M. J., Davis, J. M., Serrano, T. P. O., Ma, R., & Ridge, K. M. (2026) · European Respiratory Review · doi:10.1183/16000617.0033-2026
“Current treatment options remain limited, with only three US Food and Drug Administration-approved therapies, namely pirfenidone, nintedanib and nerandomilast [20 – 23], which slow disease progression but do not reverse established fibrosis.”
Identifying predictors of systemic sclerosis-associated interstitial lung disease
Alnaimat, F., Al-Halaseh, S., Ismail, O., et al. (2026) · Medicine · doi:10.1097/md.0000000000050368
“61] Even though steroid-sparing agents are now recommended, and despite the limited evidence on their benefit [61] chronic corticosteroid use was highly prevalent among our patients (42%).”
Collaborative functionality between three types of inflammation in idiopathic pulmonary fibrosis
Fabre, T., Wynn, T. A., & Hart, K. M. (2026) · Nature Immunology · doi:10.1038/s41590-026-02616-1 · Cited by 2
“IPF has been a highly challenging space for development of therapeutics, taking over a decade for approval of a new therapy (PDE4B, nerandomilast) in addition to nintedanib and pirfenidone 150,151 .”
Mesenchymal Stem Cell Therapy for Idiopathic Pulmonary Fibrosis: Advances and Perspectives
Zou, Y. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202625001015
“Nerandomilast, a novel selective PDE4B inhibitor approved in 2025, exerts dual anti-inflammatory and anti-fibrotic effects by elevating intracellular cAMP, while it most frequently causes diarrhea, with serious adverse events balanced across trial groups[6].”
Kinoshita, Y., Ogata, R., Eshima, K., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101504
Ge, C., & Cui, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177649
“Pirfenidone and nintedanib, together with the recently approved preferential phosphodiesterase 4B inhibitor nerandomilast, demonstrate that the clinical course of IPF is pharmaco-logically modifiable [99–101].”
What Explains the Pattern of Fibrosis in Chronic Graft‐Versus‐Host Disease?
Noorafrooz, M., Kavosi, H., & Gale, R. P. (2026) · Clinical Transplantation · doi:10.1111/ctr.70670 · Cited by 1
“A recent study of nerandomilast, an anti-inflammatory drug, reported slowing of progression of fibrosis [ 84 ].”
Lonardo, A., & Weiskirchen, R. (2026) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.70111
Zekri, S., Lahcen, N. A., Liman, W., Bianchini, F., Oubahmane, M., Hdoufane, I., & Cherqaoui, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177756
“…effects, was approved for IPF after the phase 3 FIBRONEER-IPF trial showed that it significantly slowed the decline in forced vital capacity relative to placebo, both as monotherapy and on top of existing antifibrotic therapy, providing a third, mechanistically distinct treatment option [17].”
Li, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1873614
Kim, M. J., Kwak, H. S., Kim, S., & Kim, H. C. (2026) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666261484857
Bärnthaler, T., Ding, S., Adams, T. S., Rose, K.-A., Rangel, R., Khoury, J., Salimi, M., Anderson, S., Lin, L., Velasco-Alzate, K. Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.31.747360
Kuriakose, J., Ursoleo, J. D., Isaac, B. T. J., Thangakunam, B., Sullivan, D. R., Lindell, K. O., Russell, A.-M., Hadler, R. A., Maddocks, M. M., Smirnova, N., et al. (2026) · Journal of Palliative Medicine · doi:10.1177/10966218261484821
Yang, Y., 刘森玉, Wang, S., Zhang, A., Wang, W., Zhu, Z., Zhang, X., & Liu, X. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108437
Contemporary Concise Review 2025: Interstitial Lung Disease
Magrì, T., & Richeldi, L. (2026) · Respirology · doi:10.1002/resp.70309
“However, the interaction between pirfenidone and neran-domilast reduces nerandomilast plasma concentration by at least 50%, resulting in subtherapeutic drug exposure with the 9 mg twice-daily regimen and limiting the use of this combination [43, 44].”
Self-citationGong, K., Zhu, J., Guo, H., Xu, M., Sun, T., Li, Z., Liu, Y., Li, L., Zhang, Y., Liu, C., et al. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05852-2
Self-citationKim, H.-B., Song, W., Kim, S.-O., Park, J.-H., Han, J., Lee, O., Soung, N., Yang, B., Choi, J., Schwartz, M. A., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02849-4
“1 8 Consequently, there is an urgent need to identify disease-driving molecular mechanisms and develop therapeutic strategies that target the fundamental processes underlying alveolar destruction and aberrant tissue remodeling.”
Bowden, R., Morris-Rosendahl, D. J., Hanson, H., Stanel, S. C., Gibbons, M. A., Renzoni, E. A., Chua, F., Blaikley, J., Parfrey, H., Hirani, N., et al. (2026) · Thorax · doi:10.1136/thorax-2026-225625
Serum GDF15 adds prognostic value to forced vital capacity in fibrotic interstitial lung disease
Suzuki, Y., Yoshimura, K., Mori, K., Kono, M., Matsushima, S., Kato, S., Suzuki, K., Tanaka, K., Koda, K., Masuda, T., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101510
Pitozzi, V., Caruso, P., Pontis, S., Ruscitti, F., Pittelli, M. G., Aquino, G., Volta, R., Pappani, A., Barrea, M., Quaini, F., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188158
“…well tolerated; however, their use could be associated with manageable but clinically relevant adverse events, including gastrointestinal disturbances, liver enzyme elevations, and photosensitivity, which may impact treatment adherence and require dose adjustment or supportive management [5,9–11].”
Chen, Q., Zhang, Y., Wang, S., Chen, R., Shi, Y., Li, Z., Shao, C., Gao, S., Zhou, H., & Huang, H. F. (2026) · Lung · doi:10.1007/s00408-026-00936-5
Fibrosis: Bridging fundamental mechanisms to precision medicine via advanced therapeutics
An, L., Lin, P., Chen, K., Chen, Y., Feng, Y., Liu, Z., & Wang, C. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115973 · Cited by 1
Liang, G., Tian, D., Zhu, K., Li, Y., Zeng, J., Shen, Y., Chen, Z., & Tian, Y. (2026) · Journal of International Medical Research · doi:10.1177/03000605261488118
Lin, E., Shao, Z., Liu, J., Yi, Z., Shen, L., Ying, Y., & Hu, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1917792
“The clearest recent evidence comes from nerandomilast, where phase III trials in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis showed a smaller decline in forced vital capacity over 52 weeks than placebo (Maher et al., 2025; Richeldi et al., 2025).”
The emerging role of PDE4 inhibitors for the treatment of pulmonary fibrosis
Tyker, A., Kuse, N., Pertzov, B., & Kolb, M. R. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2737175
“…from the FIBRONEER trials demonstrated that nerandomilast ameliorates FVC decline even in those already on other anti-fibrotic therapy suggesting a complimentary effect from combination therapy especially with nintedanib (perhaps less-so with pirfenidone due to drug-drug interaction) [15,16].”
InfluentialRespiratory Hospitalizations Following Initiation of Nerandomilast: A Case SeriesPreprint
Singh, J. K., Ramos, E., Kypreos, M. A., Nadeem, U., & Adams, T. N. (2026) · Research Square · doi:10.21203/rs.3.rs-11145394/v1
Small-Molecule Drugs Approved by the FDA in 2025
Wang, X., Wang, Y., Luo, R., 牛东海, Yang, L., & Wang, Z. (2026) · Molecules · doi:10.3390/molecules31193447 · Cited by 1
Interstitial lung disease exacerbations following initiation of nerandomilast: A case series
Adams, T. N. (2026) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2026.102512 · Cited by 1
Xu, J., Jin, X., Li, X., Li, Z., Zhu, B., & Tian, L. (2026) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666261491576
Kodama, K., Momozane, T., Takehara, H., & Sato, K. (2026) · International Cancer Conference Journal · doi:10.1007/s13691-026-00921-y
Distler, J. H. W., Frech, T., & McMahan, Z. H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1829186
Hamada, N., Hayashi, Y., Motooka, D., Kuwahara, A., Akira, S., & Fukushima, K. (2026) · Genes to Cells · doi:10.1111/gtc.70149
“In a Phase III trial, treatment with nerandomilast resulted in a smaller decline in forced vital capacity (FVC) compared to placebo over a 52-week period (Richeldi et al. 2025).”
Karampitsakos, Τ., Wasserman, E., Stagaki, E., Thottassery, A., Smith, J., Asif, H., SOTO, B., Guzman, C. A., Hammonds, J., Papasarantou, A., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1908302
Li, Z., 耿磊, Li, W., Wang, X., Wang, X., Qin, Z., Zhang, Y., & Mou, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1917005
“Concurrently, novel agents including nerandomilast (a PDE4B-selective inhibitor) (Maher et al., 2025; Richeldi et al., 2025), admilparant (an LPA1 antagonist) (Corte et al., 2025; Kreuter et al., 2025), and inhaled treprostinil (a PDE-5 inhibitor) (Nathan et al., 2022), exemplify the ongoing shift…”
Therapie der Lungenfibrose – Beginn einer neuen Ära
Behr, J., & Veit, T. (2026) · Pneumologie · doi:10.1055/a-2959-4770
Metadata
- Authors
- Richeldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martinez, F. J., Oldham, J. M., Valenzuela, C., Clerisme-Beaty, E., Gordat, M., Wachtlin, D., Liu, Y., Schlecker, C., Stowasser, S., Zoz, D. F., & Wijsenbeek, M. S.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Nippon Medical School (JP)
- Lyon 1 Université (FR)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University of Southern California (US)
- University of Massachusetts (UMass) Chan Medical School–UMass Memorial Health System, Worcester
- University of Michigan (US)
- Hospital Universitario de La Princesa (ES)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (France) (FR)
- Boehringer Ingelheim (United States) (US)
- Erasmus MC (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-12
- Volume
- 392
- Issue
- 22
- Pages
- 2193-2202
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4410472815
- Cited by
- 297
- References
- 20
- Citations by year
- 2026: 231 · 2025: 65
- FWCI
- 175.62
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- nerandomilast, idiopathic pulmonary fibrosis, antifibrotic therapy, nintedanib, pirfenidone, forced vital capacity, lung function, dose comparison, diarrhea, adverse events, antifibrotic agents, immunomodulatory therapy, antiproliferative therapy
- MeSH terms
- Antifibrotic Agents, Administration, Oral, Aged, Cyclobutanes, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Indoles, Lung, Male, Middle Aged, Organic Chemicals, Piperidines, Pyridones, Tablets, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis, Phosphodiesterase 4 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.